Dense deposit disease: Clinicopathologic study of 32 pediatric and adult patients

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 1, 2009, Pages 22-32

  Nasr, Samih H ^a   Valeri, Anthony M ^a   Appel, Gerald B ^a   Sherwinter, Julius ^b   Stokes, Michael B ^a   Said, Samar M ^a   Markowitz, Glen S ^a   D'Agati, Vivette D ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C3; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; AGING; ARTICLE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; COMPLEMENT BLOOD LEVEL; DENSE DEPOSIT DISEASE; FEMALE; FOLLOW UP; GLOMERULOPATHY; HEMATURIA; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; NORTH AMERICA; PREDICTION; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN URINE LEVEL; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; SEX RATIO; TISSUE LEVEL; TREATMENT RESPONSE; ADOLESCENT; AGE; BIOPSY; BLOOD; CHRONIC KIDNEY FAILURE; DRUG COMBINATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PROTEINURIA; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOPSY; CREATININE; DRUG THERAPY, COMBINATION; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HEMATURIA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PROTEINURIA; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 64049119966     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03480708     Document Type: Article

References (23)

1. Galle P: A description of a unique lesion of the glomerular basement membranes seen as a hyaline substance with the electron microscope [in French] le' sion singulie' re des membranes basales du rein et de la substance hyaline [Thesis]. Paris, Medical School, University of Paris, 1962
2. Walker PD, Ferrario F, Joh K, Bonsib SM: Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol 20: 605-616, 2007 (Pubitemid 46788867)
3. Walker PD: Dense deposit disease: New insights. Curr Opin Nephrol Hypertens 16: 204-212, 2007
4. Smith RJ, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, de Córdoba SR, Hageman GS, Jokiranta TS, Kimberling WJ, Lambris JD, Lanning LD, Levidiotis V, Licht C, Lutz HU, Meri S, Pickering MC, Quigg RJ, Rops AL, Salant DJ, Sethi S, Thurman JM, Tully HF, Tully SP, van der Vlag J, Walker PD, Wü rzner R, Zipfel PF, Dense Deposit Disease Focus Group: New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 18: 2447-2456, 2007
5. Galle P, Mahieu P: Electron dense alteration of kidney basement membranes. A renal lesion specific of a systemic disease. Am J Med 58: 749-764, 1975
6. Cameron JS, Turner DR, Heaton J, Williams DG, Ogg CS, Chantler C, Haycock GB, Hicks J: Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 74: 175-192, 1983 (Pubitemid 13192172)
7. Swainson CP, Robson JS, Thomson D, MacDonald MK: Mesangiocapillary glomerulonephritis: A long-term study of 40 cases. J Pathol 141: 449-468, 1983 (Pubitemid 14216380)
8. Habib R, Gubler MC, Loirat C, Mäiz HB, Levy M: Dense deposit disease: A variant of membranoproliferative glomerulonephritis. Kidney Int 7: 204-215, 1975
9. Davis AE, Schneeberger EE, Grupe WE, McCluskey RT: Membranoproliferative glomerulonephritis (MPGN type I) and dense deposit disease (DDD) in children. Clin Nephrol 9: 184-193, 1978
10. Klein M, Poucell S, Arbus GS, McGraw M, Rance CP, Yoon SJ, Baumal R: Characteristics of a benign subtype of dense deposit disease: Comparison with the progressive form of this disease. Clin Nephrol 20: 163-171, 1983
11. Sibley RK, Kim Y: Dense intramembranous deposit disease: New pathologic features. Kidney Int 25: 660-670, 1984 (Pubitemid 14079961)
12. The Southwest Pediatric Nephrology Study Group: Dense deposit disease in children: Prognostic value of clinical and pathologic indicators. Am J Kidney Dis 6: 161-169, 1985
13. Bennett WM, Fassett RG, Walker RG, Fairley KF, d'Apice AJ, Kincaid-Smith P: Mesangiocapillary glomerulonephritis type II (dense-deposit disease): Clinical features of progressive disease. Am J Kidney Dis 13: 469-476, 1989
14. Kashtan CE, Burke B, Burch G, Gustav Fisker S, Kim Y: Dense intramembranous deposit disease: A clinical comparison of histological subtypes. Clin Nephrol 33: 1-6, 1990 (Pubitemid 20033948)
15. Little MA, Dupont P, Campbell E, Dorman A, Walshe JJ: Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int 69: 504-511, 2006 (Pubitemid 43164442)
16. Abrera-Abeleda MA, Nishimura C, Smith JL, Sethi S, McRae JL, Murphy BF, Silvestri G, Skerka C, Józsi M, Zipfel PF, Hageman GS, Smith RJ: Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 43: 582-589, 2006 (Pubitemid 44048765)
17. McEnery PT, McAdams AJ: Regression of membranoproliferative glomerulonephritis type II (dense deposit disease): Observations in six children. Am J Kidney Dis 12: 138-146, 1988
18. Sukov WR, Gamez J, Lager DJ, Dogan A, Miller DV: Clinicopathologic and proteomic assessment of dense deposit disease associated with monoclonal gammopathy of undetermined significance [Abstract]. Modern Pathology 21: 295A, 2008
19. Kyle RA, Rajkumar SV: Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: Emphasis on risk factors for progression. Br J Haematol 139: 730-743, 2007 (Pubitemid 350115735)
20. Jokiranta TS, Solomon A, Pangburn MK, Zipfel PF, Meri S: Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol 63: 4590-4596, 1999 (Pubitemid 29474530)
21. Meri S, Koistinen V, Miettinen A, Törnroth T, Seppälä IJ: Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med 175: 939-950, 1992
22. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, Lambris JD, Lanning L, Lutz HU, Meri S, Rose NR, Salant DJ, Sethi S, Smith RJ, Smoyer W, Tully HF, Tully SP, Walker P, Welsh M, Wü rzner R, Zipfel PF: Membranoproliferative glomerulonephritis type II (dense deposit disease): An update. J Am Soc Nephrol 16: 1392-1403, 2005
23. Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr: Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone: A report of the International Study of Kidney Disease in Children. Pediatr Nephrol 6: 123-130, 1992